Abstract | INTRODUCTION: The prevalence of epilepsy increases in elderly patients aged > 65 years, and treatment is challenging because clinical data are limited. OBJECTIVE: METHODS: The safety data of seven phase II and III, double-blind, open-label, randomized clinical studies of ESL in adults were pooled. At least possibly related treatmentemergent adverse events (TEAEs) and ESL post-marketing adverse drug reactions (ADRs) were analyzed separately by age categories. RESULTS: The most frequently reported at least possibly related TEAEs in elderly (N = 120) versus non-elderly patients (N = 1863) were dizziness (10.8 vs. 20.3%), somnolence (9.2 vs. 12.6%), and hyponatremia (6.7 vs. 1.5%). Elderly patients presented a higher incidence of serious TEAEs (22.5 vs. 7.6%) and at least possibly related serious TEAEs (6.7 vs. 2.5%), probably because treatment was complicated by comorbidities and comedications. After an estimated cumulative exposure of over 2 million patient-months worldwide and 8 years of post-marketing surveillance, hyponatremia was the most frequently reported ADR (n = 232), accounting for 14.6% and 6.8% of the ADRs reported in elderly (n = 473) and non-elderly patients (n = 2406), respectively. This was followed by ADR/safety information such as drug-dose titration not performed (7.0 vs. 5.4%), product use in unapproved indication (4.9 vs. 1.9%), off-label use (3.4 vs. 2.2%), dizziness (3.4 vs. 3.5%), and seizure (2.1 vs. 5.8%). CONCLUSION: No specific safety issue was identified from the pooled studies for elderly compared with non-elderly patients. After 8 years of post-marketing surveillance, the qualitative safety of ESL remains similar to that observed in the clinical studies.
|
Authors | Luís M Magalhães, Raquel Costa, Mariana Vieira, Joana Moreira, Helena Gama, Patrício Soares-da-Silva |
Journal | Drug safety
(Drug Saf)
Vol. 44
Issue 10
Pg. 1099-1107
(10 2021)
ISSN: 1179-1942 [Electronic] New Zealand |
PMID | 34536187
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021. The Author(s). |
Chemical References |
- Anticonvulsants
- Dibenzazepines
- eslicarbazepine acetate
|
Topics |
- Adult
- Aged
- Anticonvulsants
(adverse effects)
- Dibenzazepines
- Dizziness
(chemically induced, epidemiology)
- Drug-Related Side Effects and Adverse Reactions
(epidemiology, etiology)
- Humans
- Hyponatremia
(chemically induced, drug therapy)
- Marketing
- Middle Aged
- Seizures
(chemically induced, drug therapy, epidemiology)
- Treatment Outcome
|